Renovorx, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

15 May 2026

RNXT

10-K/A: RenovoRx Files 10-K/A to Remediate Internal Control Issues

RenovoRx, Inc. filed an amendment to its 2025 Annual Report to update risk factor disclosures and provide additional details regarding the remediation of previously identified material weaknesses in internal control over financial reporting.

NASDAQ

30 Mar 2026

RNXT

Renovorx, INC

10-K: RenovoRx Reports 2025 Revenue Growth, Advances Pancreatic Cancer Trial

RenovoRx, a life sciences company, reported $1.1 million in RenovoCath sales for 2025 and continued progress in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer.

NASDAQ

1 Apr 2025

RNXT

Renovorx, INC

10-K: RenovoRx Reports Initial RenovoCath Revenue and Outlines Strategy for Growth in 2025

RenovoRx, a life sciences company, announces initial revenue from RenovoCath sales and details its plans for revenue growth and clinical trial progress in 2025.

NASDAQ

1 Apr 2024

RNXT

Renovorx, INC

10-K: RenovoRx 2023 Annual Report: Focus on TAMP Platform and Clinical Progress

RenovoRx's 2023 annual report highlights the company's focus on its TAMP platform, clinical trial progress, and financial position as it advances its lead product candidate, RenovoGem.